Pursues a research-driven business model focused on the discovery and clinical development of extended half-life monoclonal antibodies, aiming to address unmet needs in immunology and inflammation.What is the remaining capacity for future sales, and how has Dambkowski’s holding shifted over the past year? Direct holdings have declined from 331,948 shares at the start of 2025 to 271,108 after this transaction, reflecting an 18.33% reduction over the period and leaving Dambkowski with approximately 72% of his ...

华尔街最受关注、且足以影响市场走势的分析师评级报告现已汇总呈现。以下是由 The Fly 整理的、投 资者需重点关注的当日评级动态。 五大评级上调 五大评级下调 五大首次覆盖评级 1. 巴克莱 将惠而浦（W） 的评级从 "中性" 上调至 "增持"，目标股价从 104 美元上调至 123 美元。 该机构在研报中指出，惠而浦的市场份额在 2025 年实现加速增长，这一趋势有望在 2026 年延 续。 2. 奥本海默 将麦当劳（MCD） 的评级从 "与大盘持平" 上调至 "跑赢大盘"，目标股价定为 355 美 元。鉴于 2025 年餐饮板块表现欠佳，该机构对 2026 年餐饮行业的走势持更加乐观的态度。 3. 巴克莱 将劳氏（LOW） 的评级从 "中性" 上调至 "增持"，目标股价从 259 美元上调至 285 美元。 本次评级上调是巴克莱发布 2026 年综合零售、硬品零售及食品零售行业展望的配套动作。巴克莱 预计，非必需品需求将出现改善，尤其是即将落地的税收政策调整，将利好中高收入消费群体。 4. 派珀・桑德勒 将好时公司（HSY） 的评级从 "中性" 上调至 "增持"，目标股价从 193 美元上调至 213 ...

PresentationGood morning, and welcome to Apogee Therapeutics' Conference Call [Operator Instructions] Please be advised that this call is being recorded at the company's request. I will now turn the call over to Noel Kurdi, Vice President of Investor Relations at Apogee. Noel, you may begin.Noel KurdiVice President of Investor Relations Thank you, operator, and thank you all for joining us today. During this call, we'll be making forward-looking statements related to our current expectations and plans for t ...

Apogee Therapeutics (NasdaqGM:APGE) Update / Briefing January 06, 2026 08:00 AM ET Company ParticipantsDavid Nierengarten - Managing Director of Equity ResearchMichael Henderson - CEOMario Castro - Chief of Pulmonary Critical Care and Sleep Medicine DivisionNoel Kurdi - VP of Investor RelationsCarl Dambkowski - Chief Medical OfficerJeff Hartness - Chief Commercial OfficerAlex Thompson - Managing Director of BiotechnologyPhoebe Tan - Senior Biotechnology Equity Research AssociateDavid Huang - VP of Equity Re ...

Title text 2 Zumilokibart (APG777) Asthma Phase 1b Interim Results January 6, 2026 Disclaimers and Forward-looking Statements This presentation contains certain "forward-looking statements" within the meaning of applicable securities laws. Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including statements about the potential for zumilokibart (APG777) in asthma; Apogee's plans for its current and future product candidates and programs; ...

Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of FeNO through 32 weeks for patients with available follow up - Results reinforce continued development in asthma testing every 3- or 6-month dosing Successful expansion of zumilokibart beyond dermatology confirms its pipeline-in-a-product potential across I&I indications Zumilokibart in atopic dermatitis (AD) a ...

SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report interim results from its Phase 1b trial of APG777 in patients with mild-to-moderate asthma on Tuesday, January 6, 2026. Following the announcement, the Company will host a conference call and webcast at ...

Core Insights - Apogee Therapeutics Inc. (NASDAQ:APGE) is highlighted as a strong investment opportunity due to its promising pipeline and analyst confidence, with a Buy rating reiterated by TD Cowen and Canaccord Genuity [1][2]. Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologic therapies for inflammatory and immunological diseases, particularly targeting conditions like atopic dermatitis, asthma, and COPD [4]. Pipeline Developments - The company reported that its antibody APG333 demonstrated a 55-day half-life in Phase 1 trials, indicating potential for quarterly or semi-annual dosing, which is a significant advantage in treatment frequency [2]. - APG333 has shown the ability to suppress key biomarkers for up to six months with a single dose, and it has been well-tolerated with mild side effects [2][3]. Market Position and Future Prospects - The positive results from APG333 trials affirm the company's potential for delivering durable activity, which may allow for less frequent dosing compared to existing treatments [3]. - The CEO of Apogee highlighted the potential for a dosing combination of APG777 and APG333 to address respiratory diseases more effectively than monotherapy [3]. Analyst Ratings and Price Targets - Canaccord Genuity set a price target of $89 for Apogee Therapeutics, citing its strong financial position and cash reserves from a recent equity raise, alongside a promising pipeline with key data readouts expected in 2026 [1].

Core Insights - Apogee is preparing for a transformative year in 2026 with significant clinical readouts planned, including data points for their LEAP program and asthma studies [5] Group 1: Clinical Developments - In Q1 2026, Apogee will present data for their LEAP program (777) in atopic dermatitis (AD) and maintenance data, along with asthma data for the same compound [5] - Q2 2026 will feature Part B of Phase II trials, focusing on the dose response curve for 777 in AD [5] - The second half of 2026 will see a combination trial of IL-13 and OX40 ligand, with a Phase Ib trial ongoing against DUPI [5]

Apogee Therapeutics (NasdaqGM:APGE) FY 2025 Conference December 03, 2025 09:45 AM ET Company ParticipantsJeff Hartness - CCOJane Pritchett Henderson - CFOGeoff Meacham - Managing DirectorGeoff MeachamIt's the second day of the Citi Global Healthcare Conference. I'm Geoff Meacham. I'm the Senior Biopharma Analyst. My team here too, Nishant, Ross, Mary Kate. We're thrilled to have Apogee with us. We have Jane Henderson, CFO. We have Geoff Hartness, CCO. Guys, thanks for joining us. Good to see you.Jane Pritch ...